《Table 3 TB risk in Chinese patients treated with biologic agents》

  提示：宽带有限、当前游客访问压缩模式

本系列图表出处文件名：随高清版一同展现

《Biologic treatments for psoriasis in China: current status and potential tuberculosis and hepatitis B virus risks》

1. 获取 高清版本忘记账户？点击这里登录

1. 下载图表忘记账户？点击这里登录

RCT:randomized controlled trial；RS:retrospective study；PS:prospective study；OLS:Open-label study；UC:ulcerative colitis；AS，:ankylosingspondyltis；RA:rheumatoid arthritis；JIA:juvenile idiopathic arthritis；PsA:psoriatic arthritis；TB:tuberculosis；NR:not report

Current data in China demonstrate that Chinese patients treated with biologics are at greater risk for developing TB than Western populations（Table 3）.During the whole 26-week study period in the Phase III trials for infliximab，a total of 3 cases of active TB were reported as severe adverse events in 84 psoriasis patients[13].The incidence rate was3.5%，and higher than the results in the trials from US[20]，Europe[21]，and Japan[22].TB occurred 11 to 26weeks after the initiation of infliximab treatment.Among the cases，2 were reported to be pulmonary TB，while another case was reported to be TB pleurisy.In a single-center，retrospective study，1case of severe TB was identified in 24 ulcerative colitis Chinese treated with infliximab，leading to discontinuation of infliximab therapy[23].